Financial Performance - Net profit attributable to shareholders of the listed company was ¥511,789,279.65, representing a 100.40% increase year-on-year[5]. - Operating income for the period was ¥4,011,595,028.26, reflecting a growth of 4.39% compared to the same period last year[5]. - Basic earnings per share rose to ¥0.41, a 105.00% increase from ¥0.20 in the same period last year[5]. - The company reported a significant increase in net assets attributable to shareholders, which reached ¥5,556,205,568.69, up 36.52% from the previous year[5]. - The net profit attributable to shareholders increased to ¥511,789,279.65, reflecting a growth of 100.40% driven by improved product pricing and increased technical service income[12]. - The company reported a gross profit margin of approximately 10.7% for Q3 2019, compared to 10.4% in Q3 2018[21]. - Net profit for Q3 2019 was ¥191,242,716.84, compared to ¥44,166,822.03 in Q3 2018, marking a significant increase[22]. - The total profit for Q3 2019 was ¥216.40 million, compared to ¥56.76 million in Q3 2018, marking an increase of 281.5%[25]. Cash Flow - The net cash flow from operating activities for the year-to-date was ¥1,252,277,542.83, a significant recovery from a negative cash flow of ¥19,930,144.63 in the previous year[5]. - Net cash flow from operating activities reached ¥1,252,277,542.83, a significant improvement from a negative cash flow of ¥19,930,144.63 in the previous year[28]. - Total cash inflow from operating activities was ¥4,802,980,885.91, compared to ¥4,069,189,147.99 in the same period last year, reflecting a year-over-year increase of approximately 18%[28]. - Cash outflow from operating activities decreased to ¥3,550,703,343.08 from ¥4,089,119,292.62, indicating improved operational efficiency[28]. - The net cash flow from operating activities for the first three quarters was ¥1,411,193,392.06, a significant recovery from a negative cash flow of ¥6,091,379.21 in the previous year[30]. Assets and Liabilities - Total assets at the end of the reporting period reached ¥11,796,551,013.53, an increase of 13.78% compared to the end of the previous year[5]. - Total liabilities increased to ¥5,638,485,650.97 in Q3 2019 from ¥4,048,270,926.99 in Q3 2018, representing a growth of 39.2%[20]. - Current liabilities rose to ¥5,072,949,374.55 from ¥4,766,261,439.92, reflecting an increase of approximately 6.4%[18]. - Total liabilities reached approximately ¥6.16 billion, while total equity amounted to approximately ¥4.21 billion[36]. - Total non-current assets amounted to approximately 4.995 billion, contributing to total assets of approximately 8.858 billion[39]. Shareholder Information - The total number of shareholders at the end of the reporting period was 47,121[7]. - Major shareholder Chen Baohua held 25.14% of the shares, with 332,452,668 shares pledged[7]. - Total equity attributable to shareholders increased to ¥5,556,205,568.69 from ¥4,069,749,515.63, representing a growth of approximately 36.5%[18]. Investment and Expenses - Investment income showed a loss of ¥16,130,936.56, worsening by 76.88% due to increased losses from associates and joint ventures[12]. - R&D expenses for Q3 2019 amounted to ¥118,670,071.37, an increase of 19.3% from ¥99,468,976.13 in Q3 2018[21]. - The company’s financial expenses for Q3 2019 were ¥26.69 million, a decrease from ¥27.54 million in Q3 2018[24]. - The company reported a long-term investment of approximately 2.107 billion in equity investments[39]. Changes in Financial Position - The company reported a significant decrease in other payables, down to ¥185,975,702.77 from ¥1,136,205,883.75, a reduction of 83.63% due to equity payments[11]. - The capital reserve increased to ¥1,160,436,819.22 from ¥264,107,961.42, a rise of 339.38% attributed to the completion of a private placement[11]. - The company executed adjustments in financial reporting, reclassifying certain financial assets under new accounting standards, impacting the reported values of other comprehensive income[37].

Financial Performance - The company's revenue for the first half of 2019 was CNY 2,652,970,740.97, representing a 4.50% increase compared to CNY 2,538,732,136.50 in the same period last year[12]. - The net profit attributable to shareholders increased by 45.95% to approximately CNY 334.74 million compared to the same period last year[13]. - The net profit attributable to shareholders after deducting non-recurring gains and losses rose by 30.21% to approximately CNY 264.76 million[15]. - Basic earnings per share increased by 50.00% to CNY 0.27, while diluted earnings per share also rose by 50.00% to CNY 0.27[14]. - The total profit for the period was ¥429,050,999.42, compared to ¥257,624,002.25 in the same period last year, indicating a growth of approximately 66.3%[105]. - The total comprehensive income for the period was ¥351,555,220.91, compared to ¥239,844,147.23 in the previous year, representing an increase of approximately 46.6%[106]. - The company's total liabilities decreased by 16.90% to approximately ¥189.50 million compared to the previous period[45]. - The company's retained earnings increased by 16.00% to approximately ¥2.43 billion, up from ¥2.09 billion in the previous period[45]. Cash Flow and Liquidity - The company's operating cash flow turned positive with a net amount of approximately CNY 609.11 million, compared to a negative cash flow of CNY 62.92 million in the previous year[13]. - Net cash flow from operating activities improved significantly to ¥609,114,941.81, a 1,068.05% increase from -¥62,921,898.44 in the previous year[40]. - Cash inflows from operating activities amounted to ¥3.02 billion, an increase from ¥2.63 billion year-over-year[109]. - The cash balance at the end of the period was ¥1,271,415,987.98, significantly higher than the previous period's balance of ¥576,667,527.00[112]. - The company reported a net increase in cash and cash equivalents of ¥821,073,112.10, compared to an increase of ¥249,605,989.52 in the previous period[112]. Risk Management - There are no significant risks that materially affect the company's operations during the reporting period[5]. - The company has a comprehensive risk management strategy addressing quality control, new product development, and price fluctuations of raw materials[5]. - The company emphasizes the importance of risk awareness regarding forward-looking statements related to future plans and strategies[4]. - The company faces foreign exchange risks due to international operations, with measures in place to mitigate potential impacts on revenue and profit[59]. - The government-led centralized procurement model in China poses a risk to domestic sales if the company fails to win bids in future procurement processes[59]. Research and Development - The company is focused on accelerating its global strategy in formulation and enhancing its R&D capabilities in biopharmaceuticals and new drugs[18]. - The company has undertaken 5 national major new drug creation projects and applied for over 330 invention patents in the past five years[33]. - The company has initiated I phase clinical trials for 4 biopharmaceuticals and has 11 small molecule new drugs in development, with 2 entering clinical research[37]. - Research and development expenses increased by 7.07% to ¥195,475,280.12, compared to ¥182,575,932.27 in the same period last year[40]. Environmental Compliance - Actual COD emissions for the first half of 2019 were 17.59 tons, which is 50.9% of the approved total of 34.55 tons[73]. - The company has established online monitoring systems at discharge points to ensure compliance with environmental standards[79]. - The company completed one environmental impact assessment approval for a project in the first half of 2019[80]. Corporate Governance - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties[4]. - The actual controlling shareholders, Chen Baohua and Zhou Minghua, committed not to engage in any competing business activities during their tenure as major shareholders[65]. - The company confirmed that there are no ongoing business activities that compete with its main operations by its controlling shareholders[66]. - There are no significant litigation or arbitration matters reported during the reporting period[68]. Market Strategy - The company maintains a diversified sales model, including self-operated exports and partnerships with trade companies to enhance market reach[21]. - The company is actively involved in international cooperation, optimizing its product structure through mergers and acquisitions[34]. - The company is currently involved in multiple lawsuits related to the valsartan impurity incident, which are still in the response phase, and the outcomes remain uncertain[68]. Shareholder Information - The company reported a total of 38,416 common shareholders as of the end of the reporting period[88]. - The top ten shareholders hold a total of 26.58% and 19.25% of shares, with the largest shareholder, Chen Baohua, owning 332,452,668 shares[89]. - The employee stock ownership plan has 14,364,743 shares with a lock-up period of 36 months, set to be tradable on October 17, 2019[91]. Financial Reporting - The report has not been audited, ensuring transparency in financial reporting[3]. - The company has not issued any non-standard audit reports for the financial year[67]. - The company has not faced any penalties or corrective actions from regulatory bodies during the reporting period[68].

Financial Performance - Net profit attributable to shareholders decreased by 16.23% to CNY 135,596,567.20 year-on-year[4] - Operating income decreased by 3.22% to CNY 1,199,080,216.27 compared to the same period last year[4] - Basic earnings per share decreased by 15.38% to CNY 0.11 compared to the same period last year[4] - Total operating revenue for Q1 2019 was ¥1,199,080,216.27, a decrease of 3.2% compared to ¥1,239,037,519.40 in Q1 2018[20] - Net profit for Q1 2019 was ¥140,218,813.70, a decline of 13.4% from ¥161,952,179.59 in Q1 2018[21] - Earnings per share for Q1 2019 were ¥0.11, compared to ¥0.13 in Q1 2018, indicating a decrease of 15.4%[21] - Total comprehensive income for Q1 2019 was CNY 112.20 million, compared to CNY 104.78 million in Q1 2018[25] Cash Flow and Liquidity - Net cash flow from operating activities improved to CNY 232,411,982.43, a significant recovery from a negative cash flow of CNY -259,802,910.43 in the previous year[4] - Cash and cash equivalents increased by 63.50% to ¥1,489,157,470.58 from ¥910,815,139.69, primarily due to increased bank loans and collection of receivables[9] - Cash flow from operating activities in Q1 2019 was CNY 232.41 million, a significant improvement from a negative cash flow of CNY -259.80 million in Q1 2018[27] - Cash and cash equivalents at the end of Q1 2019 totaled CNY 1.46 billion, up from CNY 709.66 million at the end of Q1 2018[28] - The company reported a net cash inflow from financing activities of CNY 540.06 million in Q1 2019, compared to CNY 592.04 million in Q1 2018[28] Assets and Liabilities - Total assets increased by 5.38% to CNY 10,924,909,414.87 compared to the end of the previous year[4] - The total current assets increased to ¥5,694,650,495.80 from ¥5,212,455,641.94, indicating a growth in liquidity[14] - The company’s total liabilities increased to ¥6,582,636,517.67 from ¥6,160,709,678.53, representing a rise of about 6.9%[17] - Current liabilities rose to ¥4,913,204,919.59, compared to ¥4,766,261,439.92, indicating an increase of about 3.1%[16] - Long-term borrowings rose by 32.89% to ¥1,196,000,000.00 from ¥900,000,000.00, driven by increased working capital needs[10] Shareholder Information - The total number of shareholders at the end of the reporting period was 38,221[7] - The largest shareholder, Chen Baohua, holds 26.58% of the shares, totaling 332,452,668 shares[7] Government Support and Subsidies - The company received government subsidies amounting to CNY 40,884,129.70, which are closely related to its normal business operations[6] - Other income increased by 53.86% to ¥42,623,522.99 from ¥27,702,052.30, mainly due to an increase in government subsidies[11] Operational Efficiency - The company reported a decrease in asset impairment losses by 126.88%, reflecting a reduction in bad debt provisions for accounts receivable[11] - The company’s inventory decreased to ¥2,101,222,183.88 from ¥2,184,805,404.30, indicating improved inventory management[14] - The company reported a decrease in sales expenses to ¥186,665,595.54 in Q1 2019 from ¥200,994,073.94 in Q1 2018, a reduction of 7.1%[20] Research and Development - Research and development expenses increased to ¥98,373,751.57 in Q1 2019, up from ¥84,035,592.48 in Q1 2018, representing a growth of 17.0%[20] - Research and development expenses for Q1 2019 were CNY 36.75 million, slightly down from CNY 37.00 million in Q1 2018[24] Comprehensive Income - The company’s other comprehensive income decreased by 32.68% to ¥10,305,457.45 from ¥15,309,092.16, primarily due to a decline in the US dollar exchange rate[10] - Other comprehensive income after tax for Q1 2019 was -¥5,563,922.02, compared to -¥5,363,816.03 in Q1 2018, indicating a slight increase in losses[21]

Financial Performance - The net profit attributable to the parent company for 2018 was CNY 107,514,561.81, with a statutory surplus reserve of CNY 17,302,092.62 deducted, leaving a distributable profit of CNY 2,091,590,909.78[4] - The company did not distribute profits for the 2018 fiscal year[4] - The company reported an unallocated profit at the beginning of the year of CNY 2,209,809,882.99, with the profit distribution amount for 2017 being CNY 208,498,066.40 (including tax)[4] - The company's operating revenue for 2018 was approximately CNY 5.09 billion, representing a year-on-year increase of 1.85% compared to CNY 5.00 billion in 2017[16] - The net profit attributable to shareholders decreased by 83.18% to CNY 107.51 million in 2018 from CNY 639.25 million in 2017, primarily due to losses related to the valsartan issue[17] - The net cash flow from operating activities showed a significant decline of 89.49%, with a net cash flow of CNY 67.90 million in 2017 compared to a negative cash flow in 2018[16] - The total assets increased by 25.41% to CNY 10.37 billion at the end of 2018, up from CNY 8.27 billion at the end of 2017[16] - The company reported a basic earnings per share of CNY 0.51 in 2017, which dropped by 82.35% in 2018 due to the substantial decrease in net profit[17] - The company achieved a revenue of CNY 5.095 billion in 2018, representing a year-on-year growth of 1.85%[42] - The net profit attributable to shareholders was CNY 107.51 million, a significant decline of 83.18% compared to the previous year[42] Operational Risks and Compliance - The company faces various operational risks, including quality control, new product development, safety and environmental risks, and price fluctuations of key raw materials[6] - The company emphasizes the importance of compliance with the new accounting standards and regulations in its financial reporting[2] - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties[6] - The company has received a standard unqualified audit report from Tianjian Accounting Firm[3] - The company is committed to maintaining transparency and accuracy in its financial disclosures, as stated by its board and management[2] - The company is implementing a comprehensive risk management strategy to address quality control risks and ensure compliance with regulations[119] Research and Development - The company’s R&D focus includes multi-formulations, biopharmaceuticals, and innovative drugs, with a commitment to enhancing its global formulation strategy[24] - The company aims to enhance its R&D capabilities and accelerate the development of biopharmaceuticals and new drugs as part of its strategic initiatives[24] - The company’s R&D expenses increased by 12.28% to CNY 396.76 million, reflecting ongoing investment in innovation and product development[43] - The company has undertaken 5 national major new drug creation projects and 25 provincial science and technology projects in the past five years[34] - The company has 4 biopharmaceuticals that have obtained clinical approval, with 11 new drugs currently under research, 2 of which have entered clinical trials[69] - The company is focusing on high-end formulations and specialty generics, particularly in cardiovascular, central nervous system, anti-tumor, anti-viral, and diabetes treatment areas[69] - The company has established a comprehensive talent management system to support sustainable development, with platforms in multiple regions including the U.S. and China[35] Market Presence and Sales - The company has a 65% stake in Changxing Pharmaceutical Co., Ltd., which is a significant part of its business structure[9] - The company successfully won bids for 6 products in the national 4+7 city procurement program, enhancing its market presence[38] - The company’s global business layout progressed steadily, with operations in Europe officially launched and expansion into Southeast Asia, Hong Kong, and Africa[38] - The company has established a strong domestic sales network covering all 31 provinces and municipalities, primarily through self-owned brand products[88] - The company is actively pursuing new product development and market expansion strategies to enhance its competitive position in the pharmaceutical industry[86] Environmental and Social Responsibility - The company has increased its investment in environmental protection measures and compliance with new regulations to enhance its sustainability practices[122] - The company is committed to social responsibility, engaging in various charitable activities including disaster relief and education support[152] - The company adheres to an environmental protection philosophy of "caring for the environment and harmonious development," with no major environmental pollution incidents reported during the reporting period[153] - The company has established online monitoring systems at discharge points to ensure compliance with pollution discharge standards[160] - In 2018, the company received three environmental impact assessment approvals for various projects, demonstrating compliance with environmental regulations[162] Corporate Governance and Management - The company has not reported any significant integrity issues for itself or its controlling shareholders during the reporting period[137] - The company has maintained a good credit status, ensuring its ability to manage financial risks effectively[130] - The company’s governance structure includes independent directors who have not received remuneration from related parties, ensuring unbiased oversight[182] - The company has a performance management system in place that includes annual performance assessments and salary systems for its directors and senior management[191] - The company has seen a stable management team with several vice presidents having long tenures, contributing to consistent leadership[186][187] Future Outlook and Strategic Initiatives - The company has outlined its future plans and strategies, although these are subject to risks and uncertainties[5] - The company plans to accelerate the establishment of localized companies in Europe, Korea, Russia, the Middle East, Southeast Asia, South America, and Africa to enhance its global market presence[111] - The company aims to achieve a sales revenue target of 5.4 billion yuan for the 2019 fiscal year[119] - The company plans to expand its self-export sales, which have been increasing since obtaining self-import and export rights in 2000, focusing on markets like Europe and the U.S.[87] - The company is actively pursuing mergers and acquisitions to accelerate its external growth while ensuring internal growth[111]

Financial Performance - Operating revenue for the first nine months reached CNY 3,842,841,617.02, a year-on-year increase of 9.48%[6] - Net profit attributable to shareholders decreased by 47.38% to CNY 255,379,877.13 compared to the same period last year[6] - The company reported a decrease in net profit after deducting non-recurring gains and losses by 33.57% to CNY 271,675,657.19[6] - The company's operating revenue for Q3 2018 was approximately ¥915.19 million, an increase from ¥837.79 million in the same period last year, representing a growth of 9.4%[34] - The net profit for Q3 2018 was approximately ¥44.17 million, compared to a net loss of ¥196.52 million in Q3 2017, indicating a significant turnaround[32] - The total profit for Q3 2018 was approximately ¥76.14 million, a decrease from ¥229.65 million in Q3 2017, showing a decline of 66.8%[34] - The company reported a total comprehensive income of approximately ¥54.24 million for Q3 2018, compared to ¥191.91 million in the same quarter last year, a decrease of 71.7%[32] Cash Flow - Cash flow from operating activities showed a significant decline of 116.68%, resulting in a net outflow of CNY 19,930,144.63[6] - Cash inflow from operating activities for the first nine months of 2018 was CNY 4,069,189,147.99, an increase from CNY 3,551,224,700.10 year-over-year[38] - The net cash flow from operating activities for the first nine months of 2018 was negative CNY 19,930,144.63, a decline from a positive CNY 119,464,239.79 in the previous year[38] - Cash inflow from financing activities for the first nine months of 2018 was CNY 3,016,913,782.27, significantly higher than CNY 1,187,774,409.98 in the same period last year[39] - The net cash flow from financing activities for the first nine months of 2018 was CNY 998,785,557.97, compared to CNY 621,505,816.90 in the previous year[39] - The company’s cash outflow for operating activities totaled CNY 4,089,119,292.62, compared to CNY 3,431,760,460.31 in the previous year[38] Assets and Liabilities - Total assets increased by 19.60% to CNY 9,886,850,059.28 compared to the end of the previous year[6] - Total liabilities rose to ¥4,703,888,038.48, compared to ¥3,212,103,198.49, indicating an increase of about 46.5% year-over-year[24] - Inventory increased by 31.45% to CNY 2,095,129,297.91, reflecting expanded production and sales[11] - Long-term borrowings increased by 305.11% to CNY 900,000,000.00 due to increased funding needs[12] - Cash and cash equivalents increased to ¥365,630,451.56 from ¥330,509,262.48, showing a growth of about 10.6%[26] - Accounts receivable rose to ¥1,249,650,092.38, compared to ¥1,005,774,705.79, marking an increase of approximately 24.2%[26] - Non-current liabilities totaled ¥1,327,743,658.78, up from ¥377,014,197.68, reflecting a substantial increase of about 252%[24] Expenses and Impairments - Financial expenses increased by 33.88% to ¥104,476,214.75 due to significant bank loan growth and corresponding interest accruals[13] - Asset impairment losses surged by 957.30% to ¥95,324,924.86, primarily due to inventory write-downs influenced by FDA import bans[13] - Operating costs for the first nine months were ¥3,487,918,981.67, up from ¥3,052,422,973.38, reflecting a year-over-year increase of approximately 14.3%[30] - Research and development expenses for Q3 2018 amounted to ¥101.34 million, up from ¥59.28 million in Q3 2017, reflecting a year-over-year increase of 71.1%[34] Government Subsidies and Recalls - The company recognized a government subsidy of CNY 189,449,828.75 related to its normal business operations[8] - The company anticipates a reduction in sales by ¥169,869,300 and a decrease in net profit by ¥179,721,700 due to the valsartan recall and related customer compensations[15] - The company is actively working on the recall of valsartan products and has completed domestic recalls, with international recalls progressing[15] - The company is conducting risk assessments for new valsartan manufacturing processes in compliance with EU and FDA requirements[17]

Financial Performance - The company's operating revenue for the first half of 2018 was CNY 2,538,732,136.50, representing an increase of 8.01% compared to CNY 2,350,436,123.23 in the same period last year[19]. - The net profit attributable to shareholders of the listed company decreased by 22.37% to CNY 229,349,573.09 from CNY 295,430,702.30 in the previous year[19]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 203,336,164.92, down 19.99% from CNY 254,131,812.33 in the same period last year[19]. - Basic earnings per share decreased by 25.00% to CNY 0.18 compared to the same period last year[21]. - Net profit attributable to shareholders decreased by 22.37%, primarily due to the recall of valsartan raw materials and finished products[21]. - The company reported a significant increase in cash flow, indicating improved liquidity and operational efficiency[139]. - The company reported a net cash outflow from investment activities of CNY -596,195,632.62, slightly improved from CNY -598,002,379.22 in the previous period[152]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 9,565,253,916.00, an increase of 15.71% from CNY 8,266,827,313.24 at the end of the previous year[19]. - The company's total liabilities included accounts payable of ¥188,407,107.46, reflecting a 44.22% increase due to recalls of valsartan raw materials and finished products[69]. - Current assets increased to CNY 4,899,537,328.81 from CNY 4,072,194,611.51, representing a growth of approximately 20.3%[139]. - Total liabilities rose to CNY 4,468,371,333.06 from CNY 3,212,103,198.49, indicating an increase of approximately 39.1%[141]. Cash Flow - The net cash flow from operating activities was negative at CNY -70,441,598.44, compared to CNY -60,879,879.33 in the previous year, reflecting a decrease of 15.71%[19]. - Cash inflow from financing activities reached CNY 2,721,693,624.60, significantly higher than CNY 986,457,781.46 in the previous period, marking an increase of about 175%[152]. - Cash and cash equivalents at the end of the period amounted to CNY 1,007,175,772.86, compared to CNY 698,165,979.62 at the end of the previous period, an increase of about 44.3%[152]. Research and Development - The company focuses on the research, production, and sales of multi-formulations, biological drugs, innovative drugs, and specialty raw materials[25]. - R&D expenditure increased by 16.85% to ¥225,715,738.10, reflecting the company's commitment to innovation[60]. - The company has completed 4 new product applications and 5 product registration applications in the current year[53]. Market Position and Strategy - The company is a major global producer of raw materials for antihypertensive drugs, particularly the "pril" and "sartan" categories[25]. - The global pharmaceutical market is projected to grow from USD 793.6 billion in 2010 to USD 1.22 trillion by 2019, with a compound annual growth rate of approximately 4.45%[39]. - The company has established a comprehensive supplier management system to ensure quality and compliance in procurement[26]. Risks and Challenges - The company faces risks related to quality control due to stringent regulations from FDA, EU, and WHO, which may impact the entire process from R&D to market[78]. - New product development poses risks due to high technical difficulty, significant upfront investment, and long approval cycles, which could adversely affect returns[79]. - The fluctuation in raw material prices poses a risk to the company's operating performance, although the company has maintained stable gross margins through improved technology and management[82]. Shareholder Information - The total number of shares increased from 1,042,490,332 to 1,250,988,398 after the implementation of the profit distribution plan, which included a cash dividend of 2 RMB for every 10 shares and a bonus issue of 2 shares for every 10 shares held[117]. - The largest shareholder, Chen Baohua, held 331,102,668 shares, representing 26.47% of the total shares[124]. - The company’s employee stock ownership plan increased its holdings from 2,394,124 to 14,364,743 shares during the reporting period[120]. Environmental Compliance - The company is increasing its investment in environmental protection facilities and enhancing pollution control measures to comply with stricter regulations[81]. - All subsidiaries have established wastewater treatment facilities and online monitoring systems to ensure compliance with discharge standards[108]. - The company has a dedicated testing company to ensure regular environmental self-monitoring and compliance with regulations[111]. Management and Governance - The company appointed new executives, including Chen Dunyuan, Yang Yongtao, and Zhang Jia'ai as vice presidents in 2018[132]. - The company’s board of directors saw the election of Guo Sijia as a new director in January 2018[132]. - The company has not undergone any changes in controlling shareholders or actual controllers during the reporting period[128].

浙江华海药业股份有限公司 2018 年第一季度报告 1 / 18 | 一、 | 重要提示 | 3 | | --- | --- | --- | | 二、 | 公司基本情况 | 3 | | 三、 | 重要事项 | 5 | | 四、 | 附录 | 7 | 2018 年第一季度报告 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 2018 年第一季度报告 公司代码：600521 公司简称：华海药业 1.3 公司负责人陈保华、主管会计工作负责人张美及会计机构负责人（会计主管人员）周娟保证 季度报告中财务报表的真实、准确、完整。 1.4 本公司第一季度报告未经审计。 二、 公司基本情况 2.1 主要财务数据 √适用 □不适用 | | 单位：元 | 币种：人民币 | | --- | --- | --- | | 项目 | 本期金额 | 说明 | | 非流动资产处置损益 | -1,238,923.05 | | | 越权审批，或无正式批准文件，或偶发性的税收 ...